1. French National Agency for Safety of Health Products and Medicines Safety signal concerning the association of two antivirals, daclatasvir and/or sofosbuvir, in the treatment of chronic hepatitis C and/or amiodarone and the occurrence of cardiac arrhythmias 2015 http://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite-pour-l-evaluation-des-risques-en-matiere-de-pharmacovigilance-PRAC/Finalisation-de-la-reevaluation-des-medicaments-contenant-de-l-ambroxol-ou-de-la-bromhexine-retour-d-information-sur-le-PRAC-de-janvier-2015-Point-d-information
2. European Medicines Agency EMA recommends avoidance of certain hepatitis C medicines and amiodarone together 2015 http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002313.jsp&mid=WC0b01ac058004d5c1
3. U.S. Food and Drug Administration FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another direct acting antiviral drug http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm
4. Amiodarone prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018972s038s039lbl.pdf
5. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including rechallenge;Renet;Gastroenterology,2015